HLB INC |
End-of-day quote
Other stock markets
|
||
| - | - |
|
| Sales 2022 | 180B 131M 0 | Sales 2023 | 42.9B 31.23M 0 | Capitalization | 6,542B 4.76B 0 |
|---|---|---|---|---|---|
| Net income 2022 | -78.16B -56.9M - | Net income 2023 | -189B -138M - | EV / Sales 2022 | 17.5 x |
| Net cash position 2022 | 168B 122M 0 | Net cash position 2023 | 49.31B 35.89M 0 | EV / Sales 2023 | 151 x |
| P/E ratio 2022 |
-40.6
x | P/E ratio 2023 |
-32.5
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.2% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Yang-Gon Jin
CEO | Chief Executive Officer | 58 | - |
Hyuk Joo Jee
PRN | Corporate Officer/Principal | - | - |
Yong-Woong Kim
AUD | Comptroller/Controller/Auditor | 65 | 12-03-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William G. Hearl
BRD | Director/Board Member | 66 | - |
Yang-Gon Jin
CEO | Chief Executive Officer | 58 | - |
Jin-Gook Park
BRD | Director/Board Member | 76 | 17-03-06 |
HLB Inc is a Korea-based company mainly engaged in the manufacture and sale of lifeboats and pipes. The Company operates its business through two segments. The Composite Material segment is mainly engaged in the construction and repair of lifeboats, the manufacture and installation of pipes. The Biomedical Device Business segment is mainly engaged in the development of biopharmaceuticals, the manufacture and sale of medical devices.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.53% | 183B | |
| -3.52% | 105B | |
| +5.33% | 51.77B | |
| +16.43% | 47.29B | |
| -1.73% | 40.2B | |
| +5.66% | 27.62B | |
| -2.01% | 25.51B | |
| +9.84% | 24.73B | |
| -1.87% | 24.52B |
